Eli Lilly

We conduct our business consistent with all applicable laws and are honest in our dealings with customers, employees, shareholders, partners, suppliers, competitors and the community.

​

We pursue pharmaceutical innovation, provide high-quality products and strive to deliver superior business results.

​

We maintain an environment built on mutual respect, openness and individual integrity. This includes our concern for all people who touch or are touched by our company: customers, employees, shareholders, partners, suppliers and communities.

​Since our founding in 1978 as one of the world’s first global biotechnology companies by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases.

​

Millions of people around the world are affected by multiple sclerosis, Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS). Many people also suffer from less common diseases such as spinal muscular atrophy (SMA) and progressive supranuclear palsy (PSP).

​

We believe that no other disease area holds as much need or as much promise for medical breakthroughs as neuroscience. 

We give first thoughts to patients and their families. We strive to increase the benefits that healthcare provides them and we conduct our business to meet their diversified healthcare needs worldwide. As a human health care (“hhc”) company, we develop and provide products and services that contribute to the well-being of patients and customers under any  healthcare system.

​

In order to realize our corporate philosophy, we develop business activities that contribute to sustainable economic growth and the resolution of social issues, as well as make  decisions and act appropriately and in a timely manner, in compliance with all relevant laws and ethical standards.

The Alzheimer’s pandemic is one of the most significant health and social economic crises of this generation. It is a national and global emergency that has a devastating health, social and economic toll on millions of people living with this disease, their families and caregivers.

​

UsAgainstAlzheimer’s exists to conquer Alzheimer’s disease. Since our founding in 2010, we have taken on the toughest problems in the fight to end Alzheimer’s. Our work is driven by the urgency to find effective treatments and the prevention steps needed to reach the time where no one is lost to Alzheimer’s

​

In the past decade, progress has been made, with more hope on the horizon now than ever before.

​

But every day of delay is another day lost to the millions of people affected by this devastating disease. If nothing changes, by 2050, 14 million Americans will be living with Alzheimer’s at an annual cost of more than $1 trillion. The time to act is now.

Music Mends Minds is a nonprofit that creates musical support groups for individuals with Alzheimer’s, dementia, Parkinson’s, traumatic brain injury, PTSD, and other neurological disorders.

​

To foster worldwide communities among afflicted individuals and their families, friends, volunteers, and caregivers, all of whom can thrive on socialization and music-making.

K2 Medical Research, a privately-owned clinical research facility in the greater Orlando area. We specialize in conducting multiphasic clinical trials that promote the development of innovative and effective medical treatments while maintaining the safety and privacy of our participants.

Here at K2, we are committed to fighting the diseases that plague our loved ones and ourselves. By harnessing the power of advanced clinical research and connecting our patients with the treatments of tomorrow, we can improve the health of our local communities, and by extent, the population of our world.

Alzheimer’s disease is the most common form of dementia, with 6.2 million people in the United States living with Alzheimer’s disease today. If the current trend continues, 12.7 million Americans 65 and older will have Alzheimer’s by 2050.

​

Alzheimer’s often starts 5, 10, or even 20 years before symptoms appear, meaning early detection and a focus on brain health are key. That is why BrainGuide has developed a memory questionnaire and collected resources to help you better understand Alzheimer’s and what best next steps you can take.

​

BrainGuide is a first-of-its-kind platform created by UsAgainstAlzheimer’s with in-kind and financial support from Biogen.

Whether you are concerned about your own brain health, that of a loved one, or if you are an Alzheimer’s caregiver, BrainGuide is here to provide you with the tools you need to move forward confidently.

Lilly's Clinical Trial
TRAILBLAZER-ALZ 3 Trial

The TRAILBLAZER-ALZ 3 Trial is a research study to see if an investigation medicine can help to prevent or slow down symptoms of Alzheimer's disease. Study participants will recieve either the investigational;' medicine or placebo.

​

A research study also know as a clinical trial, helps researchers and doctors to find out if a investigational medicine is both safe and effective.

​

A placebo look s the same as the investigational drug but does not contain any actual medication.

​

To learn more, head over to the Eli Lilly's TRAILBLAZER-ALZ 3 site for more info